Falsification of biotechnology drugs: current dangers and/or future disasters?

Journal of Pharmaceutical and Biomedical Analysis
Steven JanvierEric Deconinck

Abstract

Falsified medical products have become a global threat since they were first mentioned to the general public at the conference of experts on the rational use of drugs organized by the world health organization (WHO) in 1985. Today, official estimates of the annual death toll due to falsified medical products range between two hundred thousand and one million. Although the extent of this global problem is the most significant in the developing world, an increasing number of reports have demonstrated the presence of a substantial (black) market for falsified medical products in the developed world. In recent years, also biotechnology drugs (synthetic peptide drugs and protein drugs) have been reported to be prone for falsifications. Next to the traditional doping related substances and image-enhancing polypeptides (e.g., human growth hormone, melanotan II) also essential medicines such as insulin, oxytocin and monoclonal antibodies have been falsified. The danger regarding the use of these falsified polypeptide drugs lies in the fact that end-users have no guarantee of the safety and efficacy of these preparations. Multiple reports have namely described the presence of the wrong active pharmaceutical ingredient (API), the wrong d...Continue Reading

Associated Datasets

Citations

Dec 31, 2019·Drug Testing and Analysis·Alexandre MarchandMichel Audran
Aug 31, 2020·Regulatory Toxicology and Pharmacology : RTP·Khalid K Al-KinaniRodeina Challand
Feb 15, 2021·Journal of Pharmaceutical and Biomedical Analysis·Ingrid M E Bakker-'t HartBastiaan J Venhuis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bioinformatics in Biomedicine

Bioinformatics in biomedicine incorporates computer science, biology, chemistry, medicine, mathematics and statistics. Discover the latest research on bioinformatics in biomedicine here.